Logo image of ATOS

ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

USA - NASDAQ:ATOS - US04962H5063 - Common Stock

1.08 USD
-0.1 (-8.47%)
Last: 10/10/2025, 9:10:53 PM
1.06 USD
-0.02 (-1.85%)
After Hours: 10/10/2025, 9:10:53 PM
Fundamental Rating

3

ATOS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 537 industry peers in the Biotechnology industry. ATOS has a great financial health rating, but its profitability evaluates not so good. ATOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATOS had negative earnings in the past year.
In the past year ATOS has reported a negative cash flow from operations.
In the past 5 years ATOS always reported negative net income.
In the past 5 years ATOS always reported negative operating cash flow.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ATOS has a Return On Assets (-44.51%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -49.78%, ATOS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -44.51%
ROE -49.78%
ROIC N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ATOS has been increased compared to 1 year ago.
ATOS has more shares outstanding than it did 5 years ago.
ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 6.85 indicates that ATOS is not in any danger for bankruptcy at the moment.
ATOS's Altman-Z score of 6.85 is fine compared to the rest of the industry. ATOS outperforms 78.21% of its industry peers.
ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.85
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 9.17 indicates that ATOS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.17, ATOS is in the better half of the industry, outperforming 78.21% of the companies in the same industry.
ATOS has a Quick Ratio of 9.17. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
ATOS's Quick ratio of 9.17 is fine compared to the rest of the industry. ATOS outperforms 78.40% of its industry peers.
Industry RankSector Rank
Current Ratio 9.17
Quick Ratio 9.17
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.17% over the past year.
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ATOS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19%
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%
EPS Next 5Y8.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

ATOS's earnings are expected to decrease with -16.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (10/10/2025, 9:10:53 PM)

After market: 1.06 -0.02 (-1.85%)

1.08

-0.1 (-8.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners21.17%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change18.98%
Market Cap139.50M
Analysts82
Price Target5.74 (431.48%)
Short Float %2.17%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-19.35%
Max EPS beat(2)13.5%
EPS beat(4)2
Avg EPS beat(4)3.24%
Min EPS beat(4)-19.35%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)3.4%
EPS beat(12)8
Avg EPS beat(12)1.56%
EPS beat(16)12
Avg EPS beat(16)5.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.51%
ROE -49.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.17
Quick Ratio 9.17
Altman-Z 6.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)157.54%
Cap/Depr(5y)108.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-19%
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%
EPS Next 5Y8.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.8%
OCF growth 3YN/A
OCF growth 5YN/A